Inge Haeck
Overview
Explore the profile of Inge Haeck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
102
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dekkers C, Zuithoff N, Bakker D, Knol E, Wevers A, Touwslager W, et al.
Allergy
. 2024 Dec;
PMID: 39673366
Introduction And Objectives: Tralokinumab-a biological that specifically targets interleukin-13-is one of the newer advanced systemic treatments for patients with moderate-to-severe atopic dermatitis (AD). Although safety and efficacy have been shown...
2.
Boesjes C, Kamphuis E, de Graaf M, Spekhorst L, Haeck I, van der Gang L, et al.
JAMA Dermatol
. 2024 Aug;
160(10):1044-1055.
PMID: 39110432
Importance: Limited data are available on the long-term effectiveness and safety of dupilumab for atopic dermatitis (AD) in daily practice. Objective: To evaluate clinical effectiveness and reasons for discontinuation of...
3.
Zhang J, Boesjes C, Loman L, Kamphuis E, Romeijn M, Spekhorst L, et al.
J Am Acad Dermatol
. 2024 Apr;
91(2):300-311.
PMID: 38653344
Background: Long-term daily practice data on patient-reported benefits of dupilumab for atopic dermatitis (AD) remains limited. Objective: To evaluate patient-reported outcome measures (PROMs) and the safety of dupilumab in patients...
4.
Kamphuis E, Boesjes C, Loman L, Kamsteeg M, Haeck I, van Lynden-van Nes A, et al.
Acta Derm Venereol
. 2024 Feb;
104:adv19454.
PMID: 38323500
Limited daily practice data on the effect of abrocitinib in patients with atopic dermatitis are available. The aim of this multicentre prospective study is to evaluate the effectiveness and safety...
5.
Boesjes C, Van der Gang L, Zuithoff N, Bakker D, Spekhorst L, Haeck I, et al.
Acta Derm Venereol
. 2023 Feb;
103:adv00872.
PMID: 36794894
Clinical trials showed that upadacitinib, a selective Janus kinase-1 inhibitor, is effective for treatment of moderate-to-severe atopic dermatitis. However, daily practice studies are limited. This multicentre prospective study evaluated the...
6.
Spekhorst L, de Graaf M, van der Rijst L, Zuithoff N, Schweizer R, Kamsteeg M, et al.
Clin Transl Allergy
. 2023 Jan;
13(1):e12219.
PMID: 36705510
No abstract available.
7.
Boesjes C, Kamphuis E, Zuithoff N, Bakker D, Loman L, Spekhorst L, et al.
Acta Derm Venereol
. 2022 Nov;
102:adv00820.
PMID: 36420885
Clinical trials have shown that baricitinib, an oral selective Janus kinase 1/2 inhibitor, is effective for the treatment of moderate-to-severe atopic dermatitis. However, daily practice data are limited. Therefore, this...
8.
Spekhorst L, de Graaf M, Zuithoff N, van den Reek J, Kamsteeg M, Boesjes C, et al.
JAMA Dermatol
. 2022 Aug;
158(9):1048-1056.
PMID: 35947364
Importance: Long-term data on dupilumab drug survival in patients with atopic dermatitis (AD) are scarce. Furthermore, little is known about the factors associated with drug survival of dupilumab in AD....
9.
Achten R, van Luijk C, Van der Rijst L, Bakker D, Spekhorst L, Zuithoff N, et al.
Acta Derm Venereol
. 2022 Jan;
102:adv00666.
PMID: 35098318
This study identified risk factors for the development of dupilumab-associated ocular surface disease in patients with moderate-to-severe atopic dermatitis in a large prospective daily practice cohort. Data from the Dutch...
10.
Ariens L, Bakker D, Spekhorst L, Van der Schaft J, Thijs J, Haeck I, et al.
Acta Derm Venereol
. 2021 Aug;
101(10):adv00573.
PMID: 34396421
Dupilumab treatment improves signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis. This study evaluated the impact of dupilumab treatment on absenteeism, presenteeism, and related costs in...